New article proposes a tinderbox framework for skinny-label inducement cases, offering the Supreme Court a middle path in Hikma v. Amarin. Continue reading this post on Patently-O.
by Dennis Crouch
In Hikma v. Amarin, No. 24-889, the Supreme Court is focusing on the question of when does a generic manufacturer’s decision to sell a cheaper version of a drug cross the line into a… [+3216 chars]
